Cardiovascular disease (CVD) is among the leading causes of death and disability worldwide [1] e. Cardiovascular risk (CVR) is the probability of an individual developing cardiovascular disease or experiencing cardiovascular events during a specific period [2]. Obesity is classified when the body mass...
Familial hypercholesterolemia (FH) is an inherited cholesterol metabolism disorder characterized primarily by extremely high levels of low-density lipoprotein cholesterol (LDL-C) and an increased risk of accelerated atherosclerosis and premature coronary heart disease (CHD) [1, 2–3]. The prevalence...
Familial hypercholesterolemia (FH) is the most common monogenic lipid disorder characterized by lifelong exposure to high levels of low-density lipoprotein cholesterol (LDL-C) and by an increased risk of premature atherosclerotic cardiovascular disease (ASCVD) [1]. In FH subjects different mutations...
Cardiovascular diseases (CVD) are the leading cause of death globally. An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths [1, 2]. In 2021, the prevalence rate of CVD in Germany was 22.1% in people over 65 years of age. The highest rates of CVD were observed...
The history of PCSK9 inhibition begins with pioneering genetic discoveries that clarified PCSK9's function in controlling LDL cholesterol (LDL‐C) levels and its effects on cardiovascular health [1]. In the absence of a mutation in the gene encoding LDL receptor or apolipoprotein B (APOB), certain...